188 related articles for article (PubMed ID: 32784043)
1. Optimization of the quality by design approach for gene therapy products: A case study for adeno-associated viral vectors.
Tanaka T; Hanaoka H; Sakurai S
Eur J Pharm Biopharm; 2020 Oct; 155():88-102. PubMed ID: 32784043
[TBL] [Abstract][Full Text] [Related]
2. Quality Control Testing, Characterization and Critical Quality Attributes of Adeno-Associated Virus Vectors Used for Human Gene Therapy.
Wright JF
Biotechnol J; 2021 Jan; 16(1):e2000022. PubMed ID: 33146911
[TBL] [Abstract][Full Text] [Related]
3. Analytical methods to characterize recombinant adeno-associated virus vectors and the benefit of standardization and reference materials.
Green EA; Lee KH
Curr Opin Biotechnol; 2021 Oct; 71():65-76. PubMed ID: 34273809
[TBL] [Abstract][Full Text] [Related]
4. Bound Protein- and Peptide-Based Strategies for Adeno-Associated Virus Vector-Mediated Gene Therapy: Where Do We Stand Now?
Zhang X; Chai Z; Samulski RJ; Li C
Hum Gene Ther; 2020 Nov; 31(21-22):1146-1154. PubMed ID: 32940063
[TBL] [Abstract][Full Text] [Related]
5. Development of a rapid, robust, and universal picogreen-based method to titer adeno-associated vectors.
Piedra J; Ontiveros M; Miravet S; Penalva C; Monfar M; Chillon M
Hum Gene Ther Methods; 2015 Feb; 26(1):35-42. PubMed ID: 25640021
[TBL] [Abstract][Full Text] [Related]
6. Assessment of quality attributes for adeno-associated viral vectors.
Tustian AD; Bak H
Biotechnol Bioeng; 2021 Nov; 118(11):4186-4203. PubMed ID: 34309017
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Evaluation of AAV Vectors for Retinal Gene Therapy.
Wagner JE; Schön C; Becirovic E; Biel M; Michalakis S
Methods Mol Biol; 2019; 1834():383-390. PubMed ID: 30324456
[TBL] [Abstract][Full Text] [Related]
8. [Recombinant adeno-associated virus vector related impurities].
Diao Y; Wang Q; Xiao W; Xu R
Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):717-23. PubMed ID: 21845838
[TBL] [Abstract][Full Text] [Related]
9. Leveraging rAAV bioprocess understanding and next generation bioanalytics development.
Escandell JM; Pais DA; Carvalho SB; Vincent K; Gomes-Alves P; Alves PM
Curr Opin Biotechnol; 2022 Apr; 74():271-277. PubMed ID: 35007989
[TBL] [Abstract][Full Text] [Related]
10. Sodium Chloride Enhances Recombinant Adeno-Associated Virus Production in a Serum-Free Suspension Manufacturing Platform Using the Herpes Simplex Virus System.
Adamson-Small L; Potter M; Byrne BJ; Clément N
Hum Gene Ther Methods; 2017 Feb; 28(1):1-14. PubMed ID: 28117600
[TBL] [Abstract][Full Text] [Related]
11. Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors.
Hirsch ML; Wolf SJ; Samulski RJ
Methods Mol Biol; 2016; 1382():21-39. PubMed ID: 26611576
[TBL] [Abstract][Full Text] [Related]
12. Production of clinical-grade recombinant adeno-associated virus vectors.
Snyder RO; Flotte TR
Curr Opin Biotechnol; 2002 Oct; 13(5):418-23. PubMed ID: 12459331
[TBL] [Abstract][Full Text] [Related]
13. The Platform Vector Gene Therapies Project: Increasing the Efficiency of Adeno-Associated Virus Gene Therapy Clinical Trial Startup.
Brooks PJ; Ottinger EA; Portero D; Lomash RM; Alimardanov A; Terse P; Xu X; Chandler RJ; Geist Hauserman J; Esposito E; Bönnemann CG; Venditti CP; Austin CP; Pariser A; Lo DC
Hum Gene Ther; 2020 Oct; 31(19-20):1034-1042. PubMed ID: 32993373
[No Abstract] [Full Text] [Related]
14. Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production.
Zhang H; Xie J; Xie Q; Wilson JM; Gao G
Hum Gene Ther; 2009 Sep; 20(9):922-9. PubMed ID: 19618999
[TBL] [Abstract][Full Text] [Related]
15. AAV Vectors for Efficient Gene Delivery to Rodent Hearts.
Lopez-Gordo E; Kohlbrenner E; Katz MG; Weber T
Methods Mol Biol; 2019; 1950():311-332. PubMed ID: 30783983
[TBL] [Abstract][Full Text] [Related]
16. Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines.
Kotin RM; Snyder RO
Hum Gene Ther; 2017 Apr; 28(4):350-360. PubMed ID: 28351174
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example.
De BP; Chen A; Salami CO; Van de Graaf B; Rosenberg JB; Pagovich OE; Sondhi D; Crystal RG; Kaminsky SM
Hum Gene Ther Methods; 2018 Jun; 29(3):146-155. PubMed ID: 29706115
[TBL] [Abstract][Full Text] [Related]
18. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison.
Duan D; Yue Y; Engelhardt JF
Mol Ther; 2001 Oct; 4(4):383-91. PubMed ID: 11592843
[TBL] [Abstract][Full Text] [Related]
19. Challenges in scaling up AAV-based gene therapy manufacturing.
Jiang Z; Dalby PA
Trends Biotechnol; 2023 Oct; 41(10):1268-1281. PubMed ID: 37127491
[TBL] [Abstract][Full Text] [Related]
20. [Large-scale production of recombinant adeno-associated virus (rAAV)].
Wang F; Diao Y; Xiao W; Xu R
Sheng Wu Gong Cheng Xue Bao; 2009 Nov; 25(11):1608-13. PubMed ID: 20222456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
